Latest Conference Articles

Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Selinexor improved PFS, TFST, TSST, and PFS2 in TP53 wild-type advanced/recurrent endometrial cancer.

Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.

Mirvetuximab soravtansine continues to show efficacy and safety in final analysis of the phase 2 PICCOLO study.

Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.

Rucaparib maintenance improved PFS in HRD-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.

Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.

Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.

BGB-16673 was safe and effective for the treatment of patients with relapsed/refractory Waldenström Macroglobulinemia.

Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.

A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.

The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.

Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.

The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL.

BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.

Lydia Scarfò, MD, discusses long-term data with BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.

PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.

Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.

The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.